3 results
Approved WMOCompleted
This study aims to investigate the biological efficacy and safety of eculizumab in patients with aneurysmal SAH.
Approved WMOWill not start
The primary objectives of this study are to establish the efficacy and safety of APL-2 compared to eculizumab in patients with PNH who continue to have Hb levels <10.5 g/dL despite treatment with eculizumab.
Not approvedWill not start
To induce a vaccine specific immune response, hereby we hope to introduce the possibility of a new treatment to improve patient outcome and survival.